Opinions
Benj Gallander
Fonar Corp
FONR-Q
DON'T BUY
Oct 06, 2006
Manufacture a stand-up MRI, the only one in the business. There is a good chance it will be de-listed by the end of January. Have a good product but they have difficulty making money.
$0.280
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
WATCH
Sells MRI machines to the health care industry. They're in a good niche. Have a specific technology that seems to be gaining acceptance. Reasonably well managed. Have registered for selling up to 10 million shares, but doesn't mean they will. This may be what is holding them back. Will take a few more quarters to see where they are heading.
biotechnology
pharmaceutical
DON'T BUY
An MRI company and they do a stand-up MRI. Have leading edge technology with numerous patents. Afraid that management lives in a bit of a fantasy world and think they’re God's gift to MRIs. There aren't enough companies buying their product. They lose money almost every year.
biotechnology
pharmaceutical
Advertising